地舒单抗对绝经后骨质疏松女性骨微结构(经组织厚度校正的骨小梁评分评估)的长期影响:FREEDOM及其开放标签延伸研究结果
该事后亚组分析纳入完成FREEDOM DXA子研究并继续进入开放标签延伸的绝经后骨质疏松女性,评估地舒单抗长达10年对经组织厚度校正的骨小梁评分(TBSTT)的影响。长期地舒单抗组从基线至第10年TBSTT持续升高至4.7%,BMD升高至22.4%,且TBSTT与BMD变化相关性差。治疗使高骨折风险患者比例从93.7%降至40.4%,更多患者转入中、低风险类别。
要点
- 长期地舒单抗组第4、5、6、8、10年TBSTT较基线分别升高3.2%、2.9%、4.1%、3.6%、4.7%(均P < 0.0001)。
- 长期地舒单抗组高骨折风险比例从基线93.7%降至第10年40.4%,中风险从6.3%升至53.9%,低风险从0升至5.7%(P < 0.0001)。
- 地舒单抗治疗期间BMD与TBSTT变化相关性差,TBSTT改善独立于BMD。
核心结论
- 在绝经后骨质疏松女性中,长达10年的地舒单抗治疗显著且持续改善经TBSTT评估的骨微结构,且独立于BMD,并使更多患者转入较低骨折风险类别。
研究设计与样本
- FREEDOM及其开放标签延伸(OLE)的事后亚组分析,纳入完成FREEDOM DXA子研究并继续进入OLE的绝经后骨质疏松女性。
- 长期地舒单抗组(n=150)接受地舒单抗60 mg皮下注射每6个月一次共3年,随后同剂量开放标签地舒单抗7年;交叉地舒单抗组(n=129)接受安慰剂3年,随后开放标签地舒单抗7年。
- 在FREEDOM基线、第1个月及第1-6、8、10年对腰椎DXA扫描评估BMD和TBSTT。
主要发现
- 长期地舒单抗组从基线至第4、5、6、8、10年,BMD分别升高11.6%、13.7%、15.5%、18.5%、22.4%,TBSTT分别升高3.2%、2.9%、4.1%、3.6%、4.7%(均P < 0.0001)。
- 长期地舒单抗组高骨折风险(根据TBSTT和BMD T-score)比例从基线93.7%降至第10年40.4%,中风险从6.3%升至53.9%,低风险从0升至5.7%(P < 0.0001)。
- 交叉地舒单抗组观察到相似反应。
- 地舒单抗治疗期间BMD与TBSTT的变化相关性差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In postmenopausal women with osteoporosis, up to 10 years of denosumab treatment significantly and continuously improved bone microarchitecture assessed by tissue thickness-adjusted trabecular bone score, independently of bone mineral density. Long-term denosumab treatment decreased the number of high fracture-risk patients and shifted more patients to lower fracture-risk categories. PURPOSE: To investigate the long-term effect of denosumab on bone microarchitecture assessed by tissue thickness-adjusted trabecular bone score (TBSTT) in post-hoc subgroup analysis of FREEDOM and open-label extension (OLE). METHODS: Postmenopausal women with lumbar spine (LS) or total hip BMD T-score <-2.5 and ≥-4.0 who completed the FREEDOM DXA substudy and continued in OLE were included. Patients received either denosumab 60 mg subcutaneously every 6 months for 3 years and same-dose open-label denosumab for 7 years (long-term denosumab; n=150) or placebo for 3 years and open-label denosumab for 7 years (crossover denosumab; n=129). BMD and TBSTT were assessed on LS DXA scans at FREEDOM baseline, month 1, and years 1-6, 8, and 10. RESULTS: In long-term denosumab group, continued increases from baseline to years 4, 5, 6, 8, and 10 in BMD (11.6%, 13.7%, 15.5%, 18.5%, and 22.4%) and TBSTT (3.2%, 2.9%, 4.1%, 3.6%, and 4.7%) were observed (all P < 0.0001). Long-term denosumab treatment decreased the proportion of patients at high fracture-risk (according to TBSTT and BMD T-score) from baseline up to year 10 (93.7 to 40.4%), resulting in increases in the proportions at medium-risk (6.3 to 53.9%) and low-risk (0 to 5.7%) (P < 0.0001). Similar responses were observed in crossover denosumab group. Changes in BMD and TBSTT were poorly correlated during denosumab treatment. CONCLUSION: In postmenopausal women with osteoporosis, up to 10 years of denosumab significantly and continuously improved bone microarchitecture assessed by TBSTT, independently of BMD, and shifted more patients to lower fracture-risk categories.
引用
- Hans D, McDermott M, Huang S, et al. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. Osteoporos Int. 2023. PMID: 36862192. doi:10.1007/s00198-023-06708-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。